Biologic Orthopedics Journal <p style="margin: 0px; line-height: 115%;"><span style="margin: 0px; line-height: 115%; font-family: 'Garamond',serif; font-size: 14pt;">The Biologic Orthopedics Journal is being launched as a new online resource of evidence-based research and analysis, along with thoughtful discussion and commentary related to approaches to orthopedic biologics, their use and their promotion. The Journal will provide free and open access to scholarly work, education and discussion to meet the needs of practitioners, health workers, researchers, scientists and policy makers. The journal will be managed by the Biologic Orthopedics Journal Association, which will be responsible for administering the process of article submissions, review, and publication along with the supporting complements, a website and digital platform to empower readers of the journal and connect them to critical resources.</span></p> <p style="margin: 0px; line-height: 115%;"><span style="margin: 0px; line-height: 115%; font-family: 'Garamond',serif; font-size: 14pt;">&nbsp;</span></p> <p style="margin: 0px; line-height: 115%;"><span style="margin: 0px; line-height: 115%; font-family: 'Garamond',serif; font-size: 14pt;">The Journal articulates and disseminates new science and clinical research for advancing the scholarship and practice of regenerative medicine in the field of orthopedics and to provide evidence-based best practices.<span style="margin: 0px;">&nbsp; </span>The journal also increases world-wide exposure to the innovations, experiences and perspectives of practitioners working in the field. Article submissions are encouraged from throughout the world, and be subject to peer review. As such, this journal serves as a reputable and authoritative resource to help influence clinical practice, research funding, policy, and operational decisions regarding biologics in orthopedics.&nbsp;</span></p> en-US (Scott Bryant) (Scott Bryant) Mon, 20 Dec 2021 17:33:33 +0000 OJS 60 Tissue Wrapping Augmentation for Anterior Cruciate Ligament Reconstruction <p>Anterior cruciate ligament reconstruction (ACLR) has become a popular surgery in orthopedic practice today, and the technique has evolved significantly over time. Surgical procedure, graft choice, and fixation systems have varied over the years. Nonetheless, several challenges like insufficient graft ligamentization, tunnel enlargement, and insufficient reestablishment of proprioception remain in ACLR. A vision of better graft healing and integration for improved outcomes after ACLR introduced the idea of the biological ACLR. Various techniques with growth factors, cellular therapies, or tissue augment have been researched with ACLR surgery for better integration and ligamentization. This review highlights the tissue wrapping<br />modalities currently being explored in biological ACLR.</p> George Jacob, Kazunori Shimomura, Yogesh K, Norimasa Nakamura Copyright (c) 2021 Biologic Orthopedics Journal Mon, 20 Dec 2021 00:00:00 +0000 Image Guided Injection of Anterior Cruciate Ligament Tears with Autologous Bone Marrow Concentrate and Platelets: Midterm Analysis from A Randomized Controlled Trial <p><strong>Background:</strong> There has been a recent emergence in the use of orthobiologics, including platelet-rich plasma (PRP) and bone marrow concentrate (BMC), in the treatment of various musculoskeletal conditions. The goal of this study was to determine if injection of BMC and platelet products into partial and full-thickness anterior cruciate ligament (ACL) tears can facilitate primary ligament healing in patients failing conservative care, resulting in improved outcomes compared to exercise therapy.<br /><strong>Methods:</strong> Patients were randomized to either exercise therapy or percutaneous injection of autologous BMC with PRP and platelet lysate into the ACL under fluoroscopic guidance. Pain and function were assessed at baseline and at 1, 3, 6, 12, and 24 months. Baseline and 6-month post-treatment magnetic resonance imaging (MRI) were obtained to evaluate interval healing. Laxity was assessed using the Telos device.<br /><strong>Results:</strong> There was significant improvement in functional outcomes in the BMC group, compared to base-line for LEFS at time points 3 up to 24 months s = 0.000000005), and significant improvement in pain in the BMC group at 6 (p = 0.00054), 12 (p = 0.00127), and 24 months (p = 0.002). There was no significant improvement in pain or function at any time point in the exercise therapy group. There was significant improvement in ACL MRI ImageJ quantitative assessment in the BMC group (p = 0.001) and no difference in the exercise group (p &gt; 0.05). No serious adverse events were reported.<br /><strong>Conclusion:</strong> Autologous BMC and platelet product injection into ACL tears improved patient function compared to exercise, observed through 24 months. Patients treated with BMC demonstrated quantitative improvements in post-treatment MRI scans suggestive of interval ligament healing.</p> Christopher Centeno, Matthew Lucas, Ian Stemper, Ehren Dodson Copyright (c) 2022 Biologic Orthopedics Journal Sun, 02 Jan 2022 00:00:00 +0000